Yuxin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuxin Wang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jiayu Liu
Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China
6 shared publications - Jianning Zhang
Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China
5 shared publications - Wenying Lv
Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China
3 shared publications - Shichao Su
Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China
2 shared publications - Zhao Gao
Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing, China
2 shared publications - Zhao Gao
Senior Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China
2 shared publications
Latest Publications
- Open Access
Cross-Cohort Concordance and Ambient RNA Sensitivity of Microglial Transcriptional Responses to Experimental Traumatic Brain Injury
Traumatic brain injury (TBI) causes substantial neurological disability, and identifying microglial responses shared across experimental settings can help prioritize targets for validation. We reanalyzed two public mouse cortical single-cell datasets, GSE180862 and GSE290150, using animal-level pseudobulk models, gene-set tests, and ambient-RNA sensitivity analysis. The study included 20,036 microglial-lineage cells from 18 animals, with three animals per condition and timepoint. Among 4252 jointly tested genes at 24 h, 70.84% had concordant effect directions (Spearman ρ = 0.5642), compared with a 49.98% independent-sign benchmark from the observed marginal proportions. In GSE290150, 636 of 879 initially significant genes retained a false discovery rate (FDR) below 0.05 after DecontX. A subset of 172 also had concordant directions in GSE180862, including Il1b, Ccl2, C5ar1, Gpr84, and Ctsb. On the paired 4242-gene sensitivity set, directional concordance was 70.79% before and 70.44% after decontamination; rank association changed little, whereas Pearson correlation was more sensitive to extreme estimated effects. Neither analysis established independent replication. No gene reached the FDR threshold in both studies, and the three complete gene sets were not significantly enriched after adjustment. These findings provide an evidence-ranked set of acute microglial inflammatory candidates and separate background-sensitive observations from signals suitable for spatial and functional validation.
Open AccessCross-Cohort Concordance and Ambient RNA Sensitivity of Microglial Transcriptional Responses to Experimental Traumatic Brain Injury
Traumatic brain injury (TBI) causes substantial neurological disability, and identifying microglial responses shared across experimental settings can help prioritize targets for validation. We reanalyzed two public mouse cortical single-cell datasets, GSE180862 and GSE290150, using animal-level pseudobulk models, gene-set tests, and ambient-RNA sensitivity analysis. The study included 20,036 microglial-lineage cells from 18 animals, with three animals per condition and timepoint. Among 4252 jointly tested genes at 24 h, 70.84% had concordant effect directions (Spearman ρ = 0.5642), compared with a 49.98% independent-sign benchmark from the observed marginal proportions. In GSE290150, 636 of 879 initially significant genes retained a false discovery rate (FDR) below 0.05 after DecontX. A subset of 172 also had concordant directions in GSE180862, including Il1b, Ccl2, C5ar1, Gpr84, and Ctsb. On the paired 4242-gene sensitivity set, directional concordance was 70.79% before and 70.44% after decontamination; rank association changed little, whereas Pearson correlation was more sensitive to extreme estimated effects. Neither analysis established independent replication. No gene reached the FDR threshold in both studies, and the three complete gene sets were not significantly enriched after adjustment. These findings provide an evidence-ranked set of acute microglial inflammatory candidates and separate background-sensitive observations from signals suitable for spatial and functional validation.
- Open Access
- 13 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (5) , 499
Oncolytic Herpes Simplex Virus for Glioblastoma: Molecular Engineering, Tumor Microenvironment Barriers, and Clinical Translation
Glioblastoma (GBM) remains the most aggressive primary malignant brain tumor in adults, with limited survival benefit from the current standard of care consisting of maximal safe resection, radiotherapy, and temozolomide-based chemotherapy. The highly infiltrative growth pattern, profound intratumoral heterogeneity, and strongly immunosuppressive tumor microenvironment together contribute to therapeutic resistance and frequent recurrence. In this context, oncolytic herpes simplex virus (oHSV) has emerged as a promising therapeutic platform for glioblastoma because of its dual capacity to directly lyse tumor cells and stimulate antitumor immune responses. In addition, the large viral genome and well-characterized biology of herpes simplex virus enable extensive genetic engineering to improve tumor selectivity, safety, and immunomodulatory function. In this review, we summarize the molecular design strategies that have driven the development of oHSV for glioblastoma, including attenuation of neurovirulence, enhancement of tumor-selective replication, and arming with immune-stimulatory transgenes. We further discuss the major biological barriers within the GBM tumor microenvironment that continue to limit therapeutic efficacy, with particular attention given to representative engineered oHSV platforms and the lessons learned from preclinical and early-phase clinical studies. A dedicated section examines these barriers in detail, including restricted intratumoral viral spread, antiviral innate immunity, and immunosuppressive myeloid cell dominance. We also review current efforts to improve outcomes through rational combination strategies with radiotherapy, immune checkpoint blockade, cytokine modulation, and other multimodal approaches. Although encouraging advances have been achieved, the clinical translation of oHSV therapy for glioblastoma still faces substantial challenges in patient selection, delivery optimization, response assessment, and treatment integration. A deeper understanding of virus–host–tumor interactions and more precise engineering of viral platforms may help unlock the full potential of oHSV-based therapy. Overall, oHSV represents one of the most compelling translational approaches in glioblastoma and provides a valuable framework for the development of mechanism-driven viro-immunotherapy in neuro-oncology.
- 13 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (5) , 499
Open AccessOncolytic Herpes Simplex Virus for Glioblastoma: Molecular Engineering, Tumor Microenvironment Barriers, and Clinical Translation
Glioblastoma (GBM) remains the most aggressive primary malignant brain tumor in adults, with limited survival benefit from the current standard of care consisting of maximal safe resection, radiotherapy, and temozolomide-based chemotherapy. The highly infiltrative growth pattern, profound intratumoral heterogeneity, and strongly immunosuppressive tumor microenvironment together contribute to therapeutic resistance and frequent recurrence. In this context, oncolytic herpes simplex virus (oHSV) has emerged as a promising therapeutic platform for glioblastoma because of its dual capacity to directly lyse tumor cells and stimulate antitumor immune responses. In addition, the large viral genome and well-characterized biology of herpes simplex virus enable extensive genetic engineering to improve tumor selectivity, safety, and immunomodulatory function. In this review, we summarize the molecular design strategies that have driven the development of oHSV for glioblastoma, including attenuation of neurovirulence, enhancement of tumor-selective replication, and arming with immune-stimulatory transgenes. We further discuss the major biological barriers within the GBM tumor microenvironment that continue to limit therapeutic efficacy, with particular attention given to representative engineered oHSV platforms and the lessons learned from preclinical and early-phase clinical studies. A dedicated section examines these barriers in detail, including restricted intratumoral viral spread, antiviral innate immunity, and immunosuppressive myeloid cell dominance. We also review current efforts to improve outcomes through rational combination strategies with radiotherapy, immune checkpoint blockade, cytokine modulation, and other multimodal approaches. Although encouraging advances have been achieved, the clinical translation of oHSV therapy for glioblastoma still faces substantial challenges in patient selection, delivery optimization, response assessment, and treatment integration. A deeper understanding of virus–host–tumor interactions and more precise engineering of viral platforms may help unlock the full potential of oHSV-based therapy. Overall, oHSV represents one of the most compelling translational approaches in glioblastoma and provides a valuable framework for the development of mechanism-driven viro-immunotherapy in neuro-oncology.
- Open Access
- 1 May 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (3) , 459-471
The Feasibility, Accuracy and Safety of Robot-Assisted Ventriculoperitoneal Shunt
Objective : Ventriculoperitoneal shunt (VPS) treats hydrocephalus effectively, but manual ventricular catheter placement has a high misplacement rate. This study assesses the feasibility, accuracy, and safety of robot-assisted VPS.Methods : A retrospective analysis was performed on the clinical data of 87 patients from 2022 to 2024, with 42 receiving robot-assisted VPS and 45 receiving conventional manual VPS. Logistic regression analysis was performed to identify risk factors affecting placement accuracy.Results : The robot-assisted cohort showed smaller bilateral frontal horn diameters and a lower Evans index (p<0.05). It achieved higher placement accuracy, required fewer puncture attempts, and had a lower postoperative complication rate (p0.05). Logistic regression analysis confirmed robot-assistance as a key factor for accurate catheter placement (odds ratio, 6.52; p<0.001).Conclusion : Robot-assisted VPS achieves precise placement, reduces puncture attempts and complications, and does not increase time costs, confirming its clinical feasibility, accuracy, and safety.
- 1 May 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (3) , 459-471
Open AccessThe Feasibility, Accuracy and Safety of Robot-Assisted Ventriculoperitoneal Shunt
Objective : Ventriculoperitoneal shunt (VPS) treats hydrocephalus effectively, but manual ventricular catheter placement has a high misplacement rate. This study assesses the feasibility, accuracy, and safety of robot-assisted VPS.Methods : A retrospective analysis was performed on the clinical data of 87 patients from 2022 to 2024, with 42 receiving robot-assisted VPS and 45 receiving conventional manual VPS. Logistic regression analysis was performed to identify risk factors affecting placement accuracy.Results : The robot-assisted cohort showed smaller bilateral frontal horn diameters and a lower Evans index (p<0.05). It achieved higher placement accuracy, required fewer puncture attempts, and had a lower postoperative complication rate (p0.05). Logistic regression analysis confirmed robot-assistance as a key factor for accurate catheter placement (odds ratio, 6.52; p<0.001).Conclusion : Robot-assisted VPS achieves precise placement, reduces puncture attempts and complications, and does not increase time costs, confirming its clinical feasibility, accuracy, and safety.
- Open Access
- 6 April 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (4) , e71365
Global Inequality and Future Burden of Autism Spectrum Disorders: A Frontier and Projection Analysis Based on GBD 2021
Background: Autism spectrum disorder (ASD) comprises a group of persistent neurodevelopmental conditions characterized by impairments in communication, restricted behavioral patterns, and social dysfunction. In severe cases, ASD can lead to self‐injury or suicide, imposing a significant burden on individuals, families, and society. This study aimed to comprehensively assess the temporal, demographic, and regional patterns of ASD burden from 1990 to 2021; project future trends; and provide insights into potential causes and public health strategies. Methods: Data on the incidence, prevalence, and disability‐adjusted life years (DALYs) of ASD were extracted from the Global Burden of Disease (GBD) Study 2021. Temporal trends were evaluated using estimated annual percentage change (EAPC) and Bayesian age‐period‐cohort (BAPC) modeling. We further examined burden distribution by age, sex, region, and sociodemographic index (SDI). Results: In 2021, an estimated 61.82 million individuals were living with ASD globally, with 1.16 million new cases and 11.54 million DALYs. The global age‐standardized point prevalence, incidence, and DALY rates were 788.3, 18.8, and 147.6 per 100,000 population, respectively—representing increases of 2.0%, 5.2%, and 2.1% since 1990. Regionally, the highest age‐standardized prevalence rate was observed in the High‐income Asia Pacific region, while tropical Latin America had the lowest. At the national level, Japan recorded the highest age‐standardized prevalence, whereas the Republic of Mauritius had the lowest. Conclusion: ASD poses a rising global public health challenge, with persistent regional disparities and underrecognized burden in adults and females. Current gaps in epidemiological surveillance, etiological understanding, and treatment capacity highlight the urgent need for greater governmental investment in ASD‐related research, early detection strategies, and inclusive care systems.
- 6 April 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (4) , e71365
Open AccessGlobal Inequality and Future Burden of Autism Spectrum Disorders: A Frontier and Projection Analysis Based on GBD 2021
Background: Autism spectrum disorder (ASD) comprises a group of persistent neurodevelopmental conditions characterized by impairments in communication, restricted behavioral patterns, and social dysfunction. In severe cases, ASD can lead to self‐injury or suicide, imposing a significant burden on individuals, families, and society. This study aimed to comprehensively assess the temporal, demographic, and regional patterns of ASD burden from 1990 to 2021; project future trends; and provide insights into potential causes and public health strategies. Methods: Data on the incidence, prevalence, and disability‐adjusted life years (DALYs) of ASD were extracted from the Global Burden of Disease (GBD) Study 2021. Temporal trends were evaluated using estimated annual percentage change (EAPC) and Bayesian age‐period‐cohort (BAPC) modeling. We further examined burden distribution by age, sex, region, and sociodemographic index (SDI). Results: In 2021, an estimated 61.82 million individuals were living with ASD globally, with 1.16 million new cases and 11.54 million DALYs. The global age‐standardized point prevalence, incidence, and DALY rates were 788.3, 18.8, and 147.6 per 100,000 population, respectively—representing increases of 2.0%, 5.2%, and 2.1% since 1990. Regionally, the highest age‐standardized prevalence rate was observed in the High‐income Asia Pacific region, while tropical Latin America had the lowest. At the national level, Japan recorded the highest age‐standardized prevalence, whereas the Republic of Mauritius had the lowest. Conclusion: ASD poses a rising global public health challenge, with persistent regional disparities and underrecognized burden in adults and females. Current gaps in epidemiological surveillance, etiological understanding, and treatment capacity highlight the urgent need for greater governmental investment in ASD‐related research, early detection strategies, and inclusive care systems.
- Open Access
Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions
High-grade gliomas—particularly glioblastoma (GBM)—remain refractory to standard-of-care surgery followed by chemoradiation, with a median overall survival of ~15 months. Oncolytic viruses (OVs), which selectively infect and lyse tumor cells while engaging antitumor immunity, offer a mechanistically distinct therapeutic modality. This review synthesizes clinical progress of OVs in GBM, with emphasis on oncolytic herpes simplex virus (oHSV) and coverage of other vectors (adenovirus, reovirus, Newcastle disease virus, vaccinia virus) across phase I–III trials, focusing on efficacy and safety. Key observations include the encouraging clinical trajectory of oHSV exemplars—T-VEC (approved for melanoma) and G47Δ (approved in Japan for recurrent GBM)—the multi-center exploration of the adenovirus DNX-2401 combined with programmed death-1 (PD-1) blockade, and the early-stage status of reovirus (pelareorep) and Newcastle disease virus programs. Emerging evidence indicates that oHSV therapy augments immune infiltration within the tumor microenvironment and alleviates immunosuppression, with synergy when combined with chemotherapy or immune checkpoint inhibitors. Persistent challenges include GBM’s inherently immunosuppressive milieu, limitations imposed by the blood–brain barrier, intrapatient viral delivery and biodistribution, and concerns about viral shedding. Future directions encompass programmable vector design, optimization of systemic delivery, biomarker-guided patient selection, and rational combination immunotherapy. Collectively, OVs represent a promising immunotherapeutic strategy in GBM; further gains will hinge on vector engineering and precision combinations to translate mechanistic promise into durable clinical benefit.
Open AccessOncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions
High-grade gliomas—particularly glioblastoma (GBM)—remain refractory to standard-of-care surgery followed by chemoradiation, with a median overall survival of ~15 months. Oncolytic viruses (OVs), which selectively infect and lyse tumor cells while engaging antitumor immunity, offer a mechanistically distinct therapeutic modality. This review synthesizes clinical progress of OVs in GBM, with emphasis on oncolytic herpes simplex virus (oHSV) and coverage of other vectors (adenovirus, reovirus, Newcastle disease virus, vaccinia virus) across phase I–III trials, focusing on efficacy and safety. Key observations include the encouraging clinical trajectory of oHSV exemplars—T-VEC (approved for melanoma) and G47Δ (approved in Japan for recurrent GBM)—the multi-center exploration of the adenovirus DNX-2401 combined with programmed death-1 (PD-1) blockade, and the early-stage status of reovirus (pelareorep) and Newcastle disease virus programs. Emerging evidence indicates that oHSV therapy augments immune infiltration within the tumor microenvironment and alleviates immunosuppression, with synergy when combined with chemotherapy or immune checkpoint inhibitors. Persistent challenges include GBM’s inherently immunosuppressive milieu, limitations imposed by the blood–brain barrier, intrapatient viral delivery and biodistribution, and concerns about viral shedding. Future directions encompass programmable vector design, optimization of systemic delivery, biomarker-guided patient selection, and rational combination immunotherapy. Collectively, OVs represent a promising immunotherapeutic strategy in GBM; further gains will hinge on vector engineering and precision combinations to translate mechanistic promise into durable clinical benefit.